FDA Investigator Allen F Hall

Allen F Hall has inspections in 22 countries as of 30 Aug 2023. Allen F Hall has collaborated with a combinined 4293 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
249
Last Inspection Date:
30 Aug 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America, Belgium, Bulgaria, Canada, India, Russian Federation, Netherlands, United Kingdom of Great Britain and Northern Ireland, South Africa, Brazil, Italy, Japan, France, Switzerland, Honduras, Finland, Germany, Spain, Romania, Mexico, Sweden
Co-Investigator(s):
Ademola O Daramola, Alan P Kurtzberg, Alanna Lmussawwir Bias, Alexandra B Pitkin, Alia Legaux, Allan P Kurtzberg, Allen P Hall, Amanda E Lewin, PhD, Ana M Pietsch, Anderson, Andrace Lde Yampert, Andrea A Branche, Angela Shepas, Anna Lazar, Anthony E Keller, RPh, Anthony J Ladner, Arindam Dasgupta, PhD, Armando Chavez, MS, Barbara A Rusin, Barbara Janine Breithaupt, Barbara M Frazier, Barbara M Frezior, Bonita S Chester, Brian Ravitch, Brooke K Higgins, Brunilda Torres, Carl J Montgomery, Carla J Lundi, CDR Ileana Barreto Pettit, CDR Rochelle B Young, RPh, MSA, Charles L Larson, Charles R Cote, RIC, Charma Konnor, Cheron M Portee, Cheryl D Mccall, Cheryl Llove Harris, Christian D Lynch (CDL), Christina D Mello, Christine M Smith, Christine W Twohy, Comyar Shoghi, Courtney N Long, Craig A Garmendia, Ct Viswanathan, PhD, Dana M Klimavicz, Daniel L Aisen, Dannie E Rowland, David G Whitman, David Kalins, David R Heiar, Dawn C Olenjack, Denise L Burosh, Diana L Ayala, Diane Cvan Leeuwen, Donna Ltartaglino Besone, Douglas A Campbell, Douglas C Kovacs, Dr. Gopa Biswas, PhD, Dr. Guang Gao, PhD, Dr. Sriram Subramaniam, PhD, Durell L Giles, Edward Deberry, Eric M Mueller, PharmD, Eric W Anderson, Erie E Joneson, Felix Maldonado, Finn A Slizza, Gajendiran Mahadevan, PhD, Gene D Arcy, Geoffrey K Kilili, Gerald N Mcgirl, DDS, Gulshan R Anand, Gwyn G Dickinson, Habacuc V Barrera, Herminio C Francisco, Himanshu Gupta, PhD, Hyojong Kwon, PhD, Iris C Macinnes, Jacqueline A O'shaughnessy, PhD, James A Lane, James R Fleckenstein, James R Montero, Janet K White, Janete F Guardia, Jeanne D Shaffer, Jeanne M Morris, Jennifer Alongie Vollom, Jennifer C Adams, Jennifer M Gogley, Jenny L Chisem, Jenny L Mccardell, Jocelyn E Massey, Jocelyn E Sparks, Joel D Martinez, Joey V Quitania, Jogy George, John A Iwen, John A Kadavil, PhD, John S Hartford, Jose Alopez Rubet, Joshua P Wireman, Juanj N Wu, Juanj Wu, Julian C Hanson, Ka L Wong, Kaitlyn T Dang, Kara A Scheibner, PhD, Karen M Kondas, Katherine E Jacobitz, Kathryn A Krentz, Kellia N Hicks, Kelvin Cheung, Kevin A Gonzalez, Kevin N Tran, Kevin T Gerrity, Kham Phommachanh, Kip J Hanks, Kirsten S Tharp, Kirtida Patel, Kristin M Abaonza, Lakecha N Lewis, Larry K Austin, Laureen F Kononen, Laverne Kimble, Leonard H Lavi, Li Hongpaul Yeh, PhD, Liatte Kreuger, PharmD, Linda Galindo, Linda R Kuchenthal, Linda Thai, Lisa P Oakes, Lori A Gioia, Lynette M Terry, Marc A Jackson, Jr, Marc R Dickens, Margaret M Annes, Marilyn S Babu, Mariza M Jafary, Mark C Saale, Martin K Yan, PhD, Martin K Yau, PhD, Mary Ewilkerson Brinsko, Matthew C Watson, Matthew J Gretkierewicz, Mei Chen Mu, Mendoza O Wallace, Michael F Skelly, PhD, Michael S Araneta, Michelle D Haamid, Michelle J Hines, Michelle M Noe, Michelle M Noe Varga, Minh D Phan, Mohsen Rajabi Abhari, FDA, Mpris Inspector, Muralidhara B Gavini, PhD, Myra K Casey, Nancy A Bellamy, Natalie J Ayoub, Natalie J Reese, Nathan R Moon, Ni A Khin, MD, Nicholas Fragedakis, Nicola M Fenty Stewart, Nilufer M Tampal, PhD, Omotunde I Osunsanmi, Omotunde O Osunsanmi, Paula A Trost, Paula J Bretz, Phal K Chhun, Prabhu P Raju, Raymond W Brullo, Rebecca T Davis, Robert C Steyert, Robert S Sweeton, Rochelle A Rolnik, Rodney G Raiford, Rodney T Allnutt, Roger F Zabinski, Ronald L Koller, Ronda R Loyd Jones, Ruben C Ayala, PharmD, Sam H Haidar, PhD, Samson O Oluseye, Sandra L Shire, DMD, MPA, Sara Jdent Acosta, Sarah E Mcmullen, Scott B Laufenberg, Scott K Zika, Sean P Desbrow, Selene T Torres, Shaquenta Y Perkins, Sherri N Rohlf, MD, Sonia R Peterson, Sonya L Karsik, Sparky L Bartee, Spiram Subramaniam, PhD, Sripal R Mada, PhD, Srlram Subramaniam, PhD, Stanley B Eugene, BS, BME, State Agency, Sunitha K Rajaram, PhD, Susan D Yuscius, Susan F Laska, MS, Susanne M Richardson, MSc RAC ELS, Suzie L Kent, Tawny L Colling, Teena H Aiken, Terrance L Thomas, Theressa B Smith, Thomas R Beilke, Timothy P Lafave, Timothy T Kapsala, Tonia L Sawyer, Trudy R Papson, Uros V Djekic, PhD, Urus V Djckik, Valerie L Whipp, Vickie J Kanion, Vickie L Anderson, Vien Q Le, Virgilio F Pacio, CSO, Walden H Lee, Wayne T Smith, William D Boden, William S Vitale, Wr Bowman, Xiaohan Cai, PhD, Xikui Chen (nmi), PhD, Young M Choi, PhD, Yvette E Guillermo, Yvonne T Lacour, Zerita White, Zhihao Qiu (Peter), PhD

Allen F Hall's Documents

Publish Date Document Type Title
November, 2014 FDA 483 Sotir Marchev - Form 483, 2014-11-14
May, 2011 FDA 483 Parexel Bionanalytical Services Division - Form 483, 2011-05-17
February, 2003 EIR Boston Scientific Corporation - EIR, 2003-02-28
March, 2002 EIR Roh, Daeyoung - EIR, 2002-03-21
January, 2004 FDA 483 Surgilight, Inc. - Form 483, 2004-01-05
October, 2010 EIR Biomedical Research Inst. of America - EIR, 2010-10-25
March, 2002 FDA 483 Response Roh, Daeyoung - Form 483R, 2002-03-14
April, 2004 FDA 483 Intertek USA, Inc. - Form 483, 2004-04-02
September, 2012 EIR Intertek USA, Inc. - EIR, 2012-09-28
April, 2012 EIR W. L. Gore & Associates, Inc. - EIR, 2012-04-13
January, 2007 FDA 483 Response Parexel Bionanalytical Services Division - Form 483R, 2007-01-19
October, 2003 EIR Cheung, Deanna G MD - EIR, 2003-10-10
July, 2003 FDA 483 MDS Pharma Services - Form 483, 2003-07-17
January, 2004 EIR Surgilight, Inc. - EIR, 2004-01-05
March, 2010 EIR Celerion Switzerland Ag - EIR, 2010-03-13
December, 2009 EIR Molecular Diagnostics Services, Inc. - EIR, 2009-12-07
March, 2002 FDA 483 Roh, Daeyoung - Form 483, 2002-03-01
July, 2003 EIR Allied Clinical Research - EIR, 2003-07-22
April, 2012 FDA 483 W. L. Gore & Associates, Inc. - Form 483, 2012-04-13
March, 2010 EIR MSD - EIR, 2010-03-05
January, 2007 FDA 483 Parexel Bionanalytical Services Division - Form 483, 2007-01-19
June, 2001 EIR Irvine Regional Hospital and Medical Center - EIR, 2001-06-14
November, 2003 EIR Pratha, Vijaya S MD Clinical Applications Labs Inc - EIR, 2003-11-04
June, 2004 EIR ACCUTEST RESEARCH LABORATORIES ( I ) - EIR, 2004-06-11
October, 2000 FDA 483 Biovail Contract Research - Form 483, 2000-10-27
October, 2000 FDA 483 Novopharm Limited - Form 483, 2000-10-19
October, 2010 FDA 483 Biomedical Research Inst. of America - Form 483, 2010-10-25
February, 2001 FDA 483 Mentor Worldwide LLC - Form 483, 2001-12-06
January, 2000 FDA 483 Thomas S. Tooma, M.D. - Form 483, 2000-01-13
November, 2001 EIR Yu, Alice, L. - EIR, 2001-11-16
March, 2002 EIR Mollen, Martin D., MD - EIR, 2002-03-14
March, 2002 FDA 483 Mollen, Martin D., MD - Form 483, 2002-03-14
January, 2014 EIR Purvi Mehra, MD - EIR, 2014-01-29
June, 2010 FDA 483 Michael Dean Berger MD - Form 483, 2010-06-10
June, 2001 FDA 483 Irvine Regional Hospital and Medical Center - Form 483, 2001-06-14
November, 2001 FDA 483 Yu, Alice, L. - Form 483, 2001-11-16
April, 2012 FDA 483 Response W. L. Gore & Associates, Inc. - Form 483R, 2012-04-24
January, 2007 EIR Parexel Bionanalytical Services Division - EIR, 2007-04-04
April, 2004 EIR Intertek USA, Inc. - EIR, 2004-04-02
October, 2003 FDA 483 Cheung, Deanna G MD - Form 483, 2003-10-10
November, 2003 FDA 483 Pratha, Vijaya S MD Clinical Applications Labs Inc - Form 483, 2003-11-04
January, 2002 EIR Molecular Diagnostics Services, Inc. - EIR, 2002-01-31
May, 2011 EIR Parexel Bionanalytical Services Division - EIR, 2011-05-17
November, 2014 FDA 483 Maria Opris - Form 483, 2014-11-21
July, 2003 FDA 483 Response MDS Pharma Services - Form 483R, 2003-07-17
October, 2000 EIR Biovail Contract Research - EIR, 2000-10-27
January, 2000 FDA 483 Mission Bay Mem Hospital Irb - Form 483, 2000-01-28
December, 2003 FDA 483 Coast IRB LLC - Form 483, 2003-12-17
April, 2002 FDA 483 IRB Inc - Form 483, 2002-04-25
December, 2003 EIR Coast IRB LLC - EIR, 2003-12-17
January, 2000 EIR Mission Bay Mem Hospital Irb - EIR, 2000-01-28
April, 2002 EIR IRB Inc - EIR, 2002-04-25
March, 2012 FDA 483 Michael Gordon MD - Form 483, 2012-03-16
November, 2002 FDA 483 Skaggs, David, MD - Form 483, 2002-11-07
November, 2002 EIR Skaggs, David, MD - EIR, 2002-11-21
January, 2015 EIR Bernard A Michlin, MD - EIR, 2015-01-23
July, 2003 FDA 483 Response Allied Clinical Research - Form 483R, 2003-07-22
September, 2015 FDA 483 Ardea Biosciences, Inc. - Form 483, 2015-09-25
August, 2011 FDA 483 Biomedical Research Inst. of America - Form 483, 2011-08-19
February, 2003 FDA 483 Boston Scientific Corporation - Form 483, 2003-02-28
October, 2000 FDA 483 Response Biovail Contract Research - Form 483R, 2000-11-09
September, 2015 EIR Ardea Biosciences, Inc. - EIR, 2015-09-25
July, 2003 EIR MDS Pharma Services - EIR, 2003-07-17
July, 2003 FDA 483 Allied Clinical Research - Form 483, 2003-07-22
January, 2015 FDA 483 Bernard A Michlin, MD - Form 483, 2015-01-23
August, 2015 FDA 483 Teirstein, Paul S. MD - Form 483, 2015-08-17

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.


Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more